Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids PR Newswire The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant difference betwee...
Notice of Extraordinary General Meeting in Orexo AB (publ) PR Newswire UPPSALA, Sweden , Oct. 3, 2023 /PRNewswire/ -- Orexo AB (publ), Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on ...
Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023 PR Newswire UPPSALA, Sweden , Sept. 5, 2023 /PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) , today announces the company will participate in Pareto Securit...
Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product PR Newswire UPPSALA, Sweden , Aug. 29, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office...
Orexo's patent win for ZUBSOLV® appealed PR Newswire UPPSALA, Sweden , July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
2023-07-18 03:01:56 ET Orexo AB press release ( OTCQX:ORXOY ): Q2 GAAP EPS of -SEK 0.37. Revenue of SEK 157.7 million (+6.7% Y/Y). Positive EBITDA of SEK 5.6 million in Q2 (SEK -32.5 million Q2, 2022, and SEK -41.1 million Q1, 2023). Cash flow from operating ...
Orexo Q2 2023 Interim Report PR Newswire UPPSALA, Sweden , July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total net revenues of SEK 157.7 m (147.8) › &...
Orexo wins patent litigation for ZUBSOLV® in the US PR Newswire The court found Orexo´s patents valid and infringed by Sun The outcome once again confirms the strength of the company´s intellectual property rights and the ability to develop innovative p...
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22 nd are now available for online viewing. REGISTER NOW AT : https://...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGIST...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...